Chemomab Therapeutics

Chemomab management will be meeting with institutional investors and potential partners in San Francisco from January 13-16, 2025. To schedule an investor meeting, please email us at ir@chemomb.com. For companies interested in connecting, please reach out through the BIO Partnering@JPM Week platform at https://bpjw.bio.org/ or contact us directly. We look forward to seeing you in San Francisco! #JPM2025 #Healthcare #chemomab #BioPartnering

Chemomab will be participating in Oppenheimer's Movers in Rare Disease Summit on Thursday, December 12, 2024, at the Westin Grand Central in New York City. This invitation-only event will feature a day of panels, presentations and 1-on-1 investor meetings. We have been selected as one of the companies with “key, near-term, potentially stock-moving catalysts" that will present an Elevator Pitch and we will be available for one-on-one meetings with attendees. For more information, see https://lnkd.in/evmEii_y

At the AASLD The Liver Meeting®2024, primary sclerosing cholangitis (PSC) expert Dr. Chris Bowlus gave an oral, late-breaking presentation of data from the CM-101 Phase 2 SPRING trial in patients with PSC (see photo below). Dr. Bowlus described how CM-101 was well tolerated and it demonstrated dose-dependent anti-inflammatory, anti-fibrotic and anti-cholestatic effects. PSC patients with moderate advanced disease treated with CM-101 showed broad and consistent improvement in biomarkers associated with clinical outcomes. He concluded these findings support further clinical development of CM-101 in patients with PSC. Chemomab CMO Matt Frankel, MD, noted, “CM-101 is the first investigative therapy for PSC to demonstrate such broad activity across a range of biomarkers representing all major components of the disease..and we look forward to meeting with the FDA before the end of the year to agree on a path forward to a PSC registrational trial." For more information see https://lnkd.in/esNSMQZU

Chemomab CEO Adi Mor is featured in a new interview conducted by one of Proactive Investors business reporters. Click on the following link for Adi's recap of highlights of our third quarter results https://lnkd.in/ebyaFg7x

Chemomab reported its Q3 2024 financial results and corporate update today. The 3rd quarter has been a busy and important period, as we reported positive topline results of the CM-101 PSC Phase 2 SPRING trial, raised $10M in a financing that extended our cash runway through early 2026 and prepared for our End of Phase 2 meeting with the FDA, scheduled for later this year. We remain on track to achieve 2 upcoming milestones in the 1st quarter of 2025 – clarification from the FDA on the design of our PSC Phase 3 registrational trial and the readout of data from the SPRING trial open label extension. If all goes well, we hope to launch the Phase 3 trial before the end of 2025 and are aiming for a possible accelerated approval single study with non-invasive surrogate biomarker endpoints. Stay tuned! For see today's press release click on this link - https://lnkd.in/dTdhFZTV

Chemomab will be reporting third quarter 2024 financial results and providing a business update on November 14, 2024 via a press release we will issue at 7:00 am ET that day. Check out our IR website on November 14 at https://lnkd.in/ecfHf9vc to see the financial results press release.

On October 29, 2024 -- Global PSC Awareness Day, we salute the worldwide PSC community -- patients, families, caregivers, medical professionals, researchers and advocates -- for their tireless efforts to advance education and effective treatments to change the course of PSC for all those affected. The Chemomab family is proud to be part of this movement! #PSCaware

We just learned that our late-breaking abstract discussing the promising results from our CM-101 Phase 2 SPRING trial in primary sclerosing cholangitis has been selected for an oral presentation on Nov. 18 at the most important scientific/medical conference on liver diseases in the U.S. - the 2024 AASLD-The Liver Meeting®. This is another exciting indicator of the potential of CM-101 to become the first disease-modifying therapy for this terrible disease that lacks any FDA-approved treatments. For more information, see https://lnkd.in/dTWpAXdU

Chemomab is delighted to be participating in the upcoming 2024 PSC Partners 20th Anniversary Annual Conference, to be held October 18-20, 2024, in Phoenix, AZ. Chemomab Chief Medical Officer Dr. Matt Frankel will present an overview of the results of the CM-101 Phase 2 SPRING trial in people with primary sclerosing cholangitis (PSC) in the Friday. October 18 General Session on Industry Updates: Ongoing Clinical Trials in PSC, scheduled from 4:25-5:30pm MT. If you are attending the conference, be sure to introduce yourself to Matt! For more information see https://lnkd.in/eWEWzi52

The fall investor conference season is in full swing and we have 2 more investor events scheduled for October - on October 9 members of our senior management team will meet with investors at the Roth Healthcare Opportunities Conference in New York City and on October 16 CEO Adi Mor will participate in a fireside chat with analyst Michael Okunewitch at the Maxim Healthcare Virtual Summit. For more information click here https://lnkd.in/eEEiHJRX